<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<tmx version="1.4">
<header creationtool="ABBYY Aligner" creationtoolversion="1.0" segtype="sentence" o-tmf="ATM" adminlang="en-US" srclang="en-US" datatype="plaintext">
</header>
<body>
<tu>
<tuv xml:lang="en-US"><seg>Genetic Changes May Dictate Course of Acute Myeloid Leukemia
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>基因改变可能影响急性粒细胞白血病进展
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Findings could help determine which therapies will benefit certain patients  </seg></tuv>
<tuv xml:lang="zh-CN"><seg>这个发现可帮助决定什么样的治疗对一些病人更有效
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>WEDNESDAY, April 30 -- Breakthroughs in understanding the extremely fine genetic underpinnings of acute myeloid leukemia may allow doctors to quickly decide which existing therapies will most benefit individual patients.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>四月三十日周三电五月一日出版的《新英格兰医学杂志》发表了两个新的研究，确定了几个与急性粒细胞白血病相关的基因突变。这是对急性粒细胞白血病超精细基因结构了解的重大进展，将使医生能快速决定现有的哪种治疗对某个病人最有益。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>"This can now help the bedside physician pick a course of action" using existing drugs, said Dr. Barton Kamen, chief medical officer of the Leukemia &amp; Lymphoma Society. </seg></tuv>
<tuv xml:lang="zh-CN"><seg>Barton Kamen是白血病淋巴瘤协会的首席医疗专家。他说，“这种进展现在可以帮助临床医生选择合适的治疗方案，这些方案使用现有的药物。</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>"It's telling us, with the tools we have at hand, who needs more [therapy] and where the risk is worth it."
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>最新的进展正告诉我们，使用现有的手段，谁需要更多的治疗，以及治疗是否利大于弊。”
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Eventually, added Kamen, pharmaceutical companies may be able to produce drugs to specifically target the genetic mutations.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>最后，Kamen补充到，制药公司可以生产专门针对这些基因的药物。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Acute myeloid leukemia, or AML, is a cancer of the bone marrow that is diagnosed in about 13,000 people in the United States each year. </seg></tuv>
<tuv xml:lang="zh-CN"><seg>急性粒细胞白血病，简称AML，是一种骨髓中的恶性肿瘤。美国每年有大约13 000人被诊断患急粒。</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>The incidence of the disease increases with age, while the survival rate decreases. </seg></tuv>
<tuv xml:lang="zh-CN"><seg>随着年龄增长，急粒发病率逐渐上升，而生存率下降。</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Only 10 percent of people with AML over the age of 60 will survive two years, according to Kamen.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>Kamen说，只有10%的60岁以上急粒患者能存活过两年。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Scientists used to see eight kinds of AML under the microscope, but with advances in genetic knowledge, they now realize there are many more forms of the disease.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>过去，科学家可在显微镜下分辨8种类型的急粒，但随着基因科学的发展，科学家们认识到，实际上急粒的类型要比8种多得多。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>In about half of AML patients, chromosomal changes help guide doctors to select specific therapies. </seg></tuv>
<tuv xml:lang="zh-CN"><seg>大约一半的急粒患者存在染色体变化，这可以帮助医生选择针对性疗法进行治疗。</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Deciding which treatments are best for the remaining half of patients whose cancers don't have chromosomal abnormalities remains a challenge.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>但决定哪种治疗对另一半染色体无异常的患者最有效，这仍然是个挑战。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>"We don't know whether they will do well or not with current treatment," said Dr. Guido Marcucci, lead author of one of the studies and associate professor of medicine at Ohio State University's Comprehensive Cancer Center. "That is why we and other groups are looking at genetic mutations or changes in [gene] expression to predict the outcome of patients with no chromosomal abnormalities."
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>“我们并不清楚，现在的治疗对这些患者是否有效”Guido Marcucci博士是俄亥俄州立大学癌症综合研究中心的副教授，是其中一个研究的第一作者，他对记者说，“这就是我们和其他小组寻找基因突变或基因表达变化，来预测没有染色体异常的患者预后的原因。”
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Marcucci and his team analyzed bone marrow and blood samples of 64 patients with AML who were younger than 60 and had leukemia cells with normal-looking chromosome structure. </seg></tuv>
<tuv xml:lang="zh-CN"><seg>Marcucci和他的团队分析了64位60岁以下急粒患者的骨髓和血液样品。他们的白血病细胞染色体结构外观正常。</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>The goal: To see if microRNA profiles might help determine which treatments were best suited for which patients, and which patients were most prone to relapse.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>分析的目标是观察微小RNA谱是否能辅助决定哪种治疗最适合某个病人，以及哪个病人最有复发倾向。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>MicroRNAs are RNAs that do not translate into proteins (unlike encoding RNAs), but instead bind to coding RNAs and shut off their ability to regulate protein production, Marcucci explained.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>微小RNA是不转义为蛋白质的RNA（与编码RNA不同），但能约束编码RNA，使它们失去调节蛋白质生成的能力，Marcucci解释到。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>"We hypothesized that microRNA contributes to damage in the functioning of hematopoietic cells (stem cells that give rise to different blood cell types) by being too low or too highly expressed," he said.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>他说，“我们猜测，微小RNA与造血细胞（即可生长为不同类型血细胞的干细胞）功能损伤有关，原因是其表达不足或过度表达”
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>And, in fact, the Ohio State team identified seven "families" (or clusters) of microRNA whose expression was associated with better (in the case of one family) or worse (six families) outcomes.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>实际上，俄亥俄州的小组确定了七族（或者类）的微小RNA，其中一族的表达产生较好预后，另外六族的表达使预后变差。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>The findings were then validated in a separate group of patients.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>这些发现之后在另一组病人中得到验证。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>The researchers were also able to ascertain that the microRNAs in question are involved in regulating genes that play a role in the immune system. </seg></tuv>
<tuv xml:lang="zh-CN"><seg>研究人员还可确定，涉及的微小RNA与一个基因的调节有关，这个在免疫系统中起作用。 </seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>"These microRNAs may affect native immunity function," Marcucci said.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>“这些微小RNA，可能会影响天然免疫功能”， Marcucci说。</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>That raises the very interesting and pertinent question that some drugs that target the immune system might have an effect on AML cells.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>这就提出了一个非常有意思而又密切相关的问题：一些针对免疫系统的药物可能对急粒细胞也有影响。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>The second study, conducted by the German-Austrian Acute Myeloid Leukemia Study Group, was a large one, involving 872 adults under the age of 60 with AML with different genetic profiles.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>第二个研究是由德国奥地利急性粒细胞白血病联合研究组进行的。这个研究规模较大，有872位60岁以下急粒患者参与，他们具有不同的基因谱。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Participants were enrolled in one of four different trials, each of which involved a stem-cell transplantation. </seg></tuv>
<tuv xml:lang="zh-CN"><seg>参与者被编入四组不同的实验中，每组实验中都进行了干细胞移植。</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>The overall remission rate was 77 percent, but this rate differed depending on the genetic make-up of the cancer.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>治疗的总体缓解率是77%，但缓解率随癌症的基因情况不同而不同。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Two different subtypes had four-year survival rates of 60 percent and 62 percent; in these groups, stem cell transplantation conferred no added benefit.
</seg></tuv>
<tuv xml:lang="zh-CN"><seg>两个不同的亚型四年生存率为60%和62%，对这两组患者，干细胞移植没有带来额外的益处。
</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Patients with two other genotypes, on the other hand, had much poorer prognoses, with four-year relapse-free survival rates of 24 percent or 25 percent and overall survival rates of 24 and 33 percent, respectively. </seg></tuv>
<tuv xml:lang="zh-CN"><seg>但另两个基因型的患者的预后更不理想，四年无复发生存率为24%和25%，总体生存率分别为24%和33%。</seg></tuv>
</tu>
<tu>
<tuv xml:lang="en-US"><seg>Stem cell transplantation did help some of these patients.</seg></tuv>
<tuv xml:lang="zh-CN"><seg>干细胞移植对其中一些患者没有疗效。
</seg></tuv>
</tu>
</body>
</tmx>